Cargando…

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

BACKGROUND: CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor. This Phase IIa study assessed the effects of CHF6001 on markers of inflammation in induced sputum and blood in patients with chronic obstructive pulmonary disease (COPD). METHODS: This was a multicentre, three-period (each 32 days...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Dave, Beeh, Kai Michael, Colgan, Brendan, Kornmann, Oliver, Leaker, Brian, Watz, Henrik, Lucci, Germano, Geraci, Silvia, Emirova, Aida, Govoni, Mirco, Nandeuil, Marie Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688371/ https://www.ncbi.nlm.nih.gov/pubmed/31399091 http://dx.doi.org/10.1186/s12931-019-1142-7

Ejemplares similares

Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis
por: Govoni, Mirco, et al.
Publicado: (2020)

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
por: Singh, Dave, et al.
Publicado: (2020)

COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition
por: Singh, Dave, et al.
Publicado: (2020)

COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type‐2 and PDE4 gene expression in sputum
por: Singh, Dave, et al.
Publicado: (2020)

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers
por: Mariotti, Fabrizia, et al.
Publicado: (2018)

Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation
por: Jolling, Koen, et al.
Publicado: (2019)

Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
por: Facchinetti, Fabrizio, et al.
Publicado: (2021)

Anti‐inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus‐inducible cytokines
por: Edwards, Michael R., et al.
Publicado: (2016)

Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)
por: Beeh, Kai M, et al.
Publicado: (2018)

CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice
por: Stellari, Fabio F., et al.
Publicado: (2019)

“All I want for Christmas is Two”: The Advent of Novel Fixed-Combination Inhalers for COPD and Outlook for 2014
por: Beeh, Kai M.
Publicado: (2013)

A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
por: Singh, Dave, et al.
Publicado: (2020)

Are the measurement properties of incremental exercise tests similar between patients with COPD and CHF?
por: Harvey-Dunstan, Theresa C, et al.
Publicado: (2019)

Evaluation of PDE4 inhibition for COPD
por: Wang, Desuo, et al.
Publicado: (2006)

Treating COPD with PDE 4 inhibitors
por: Brown, William M
Publicado: (2007)

Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study
por: Beghé, Bianca, et al.
Publicado: (2013)

Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis
por: Watz, Henrik, et al.
Publicado: (2020)

Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan
por: Tseng, Sung-Pin, et al.
Publicado: (2009)

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial
por: Beeh, Kai-Michael, et al.
Publicado: (2021)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Effect of GM6001 on the expression of syndecan-1 in rats with acute kidney injury and its protective effect on the kidneys
por: Zhang, Kunying, et al.
Publicado: (2020)

Effects of high- and moderate-intensity exercise on central hemodynamic and oxygen uptake recovery kinetics in CHF-COPD overlap
por: Mazzuco, A., et al.
Publicado: (2020)

Synthesis of CHF(2)-substituted 3-azabicyclo[3.1.0]hexanes by photochemical decomposition of CHF(2)-pyrazolines
por: Zheng, Yang, et al.
Publicado: (2018)

How inhaled corticosteroids target inflammation in COPD
por: Lea, Simon, et al.
Publicado: (2023)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Does impaired O(2) delivery during exercise accentuate central and peripheral fatigue in patients with coexistent COPD-CHF?
por: Oliveira, Mayron F., et al.
Publicado: (2015)

A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
por: Ferguson, Gary T, et al.
Publicado: (2021)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

The Saccharomyces cerevisiae W303-K6001 cross-platform genome sequence: insights into ancestry and physiology of a laboratory mutt
por: Ralser, Markus, et al.
Publicado: (2012)

Reading Level and Suitability of Congestive Heart Failure (CHF) Education in a Mobile App (CHF Info App): Descriptive Design Study
por: Athilingam, Ponrathi, et al.
Publicado: (2019)

Telecare for Diabetes, CHF or COPD: Effect on Quality of Life, Hospital Use and Costs. A Randomised Controlled Trial and Qualitative Evaluation
por: Kenealy, Timothy W., et al.
Publicado: (2015)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
por: Watz, Henrik, et al.
Publicado: (2017)

Safety of indacaterol in the treatment of patients with COPD
por: Donohue, James F, et al.
Publicado: (2011)

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial
por: Beeh, Kai M, et al.
Publicado: (2014)

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
por: Beeh, Kai M, et al.
Publicado: (2012)

892. Epidemiology, clinical features, and outcomes of Rhinovirus/Enterovirus in older adults hospitalized with acute respiratory infections and those with CHF and COPD exacerbations
por: Ess, Gabby, et al.
Publicado: (2023)

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)

cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features
por: Nourian, Yazdan Hasani, et al.
Publicado: (2023)

Measuring dobutamine (Db) clearance during continuous hemofiltration (CHF)
por: Van der Linden, T, et al.
Publicado: (1998)

Electrocardiographic and other Noninvasive Hemodynamic Markers in Decompensated CHF Patients
por: Piccirillo, Gianfranco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_efl990ap18c2qk08g8rpecoqa5